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Several clinical studies have demonstrated that the humanized anti-interleukin-6 (IL-6) receptor antibody tocilizumab (TCZ)
improves clinical symptoms and prevents progression of joint destruction in rheumatoid arthritis (RA). However, the precise
mechanism by which IL-6 blockade leads to the improvement of RA is not well understood. IL-6 promotes synovitis by inducing
neovascularization, inﬁltrationofinﬂammatorycells,andsynovialhyperplasia. IL-6causesboneresorptionbyinducingosteoclast
formation via the induction of RANKL in synovial cells, and cartilage degeneration by producing matrix metalloproteinases
(MMPs) in synovial cells and chondrocytes. Moreover, IL-6 is involved in autoimmunity by altering the balance between Th17
cells and Treg. IL-6 also acts on changing lipid concentrations in blood and on inducing the production of hepcidin which causes
iron-deﬁcient anemia. In conclusion, IL-6 is a major player in the pathogenesis of RA, and current evidence indicates that the
blockade of IL-6 is a beneﬁcial therapy for RA patients.
1.Introduction
Rheumatoid arthritis (RA) is a chronic, systemic autoim-
mune inﬂammatory disorder that may aﬀect many tissues
and organs, but principally attacks the synovium of joints.
The process induces synovitis (inﬁltration of inﬂamma-
t o r yc e l l ss u c ha sm a c r o p h a g e sa n dl y m p h o c y t e s ) ,s y n o v i a l
hyperplasia with neovascularization, and excess synovial
ﬂuid, which causes joint swelling, stiﬀness, and pain. The
ﬁnal results are the destruction of articular cartilage and
the erosion of bone in the joints, with some patients
suﬀering permanent disability. RA patients may develop
multiplesystemicsymptomsincludingfever,fatigue,anemia,
anorexia, osteoporosis, weight loss, and muscle weakness.
Patient lifespan is reduced by up to 10 years because of
cardiovascular disease resulting from chronic inﬂammation
[1]. If untreated, by 5 years after diagnosis about 40% of
patients are unable to work, and by 10 years, over 50% are
unable to work. Recently, drug management aims to relieve
symptoms, as pain relief is the priority for people with RA,
and to modify the disease process.
Although the etiology of RA is not fully understood,
it has been demonstrated that IL-6 plays a crucial role in
its pathogenesis. In fact, treatment of RA patients with
the humanized anti-interleukin-6 receptor (IL-6R) anti-
body, tocilizumab (TCZ), is highly eﬀective [2, 3]. IL-6
is a multifunctional cytokine with biological activities that
include regulation of immune response, inﬂammation, and
hematopoiesis. IL-6 also stimulates the secretory activity of
the hypothalamus-pituitary-adrenal gland axis and increases
adrenocorticotropic hormone and cortisol. IL-6 possesses
several proinﬂammatory properties, such as stimulating
the production of chemokines and adhesion molecules in
lymphocytes [4], inducing acute-phase proteins in liver cells
[5] and increasing neutrophil counts in the blood [6].
In this paper, we summarize the biological function of
IL-6 in RA pathogenesis and the mode of action of TCZ on
RA patients based on our and others’ recent research.2 Arthritis
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Figure 1: IL-6 signaling.
2. IL-6SignalTransduction
IL-6 exerts its biological activities through two molecules,
a IL-6-speciﬁc receptor and a signal transducer, gp130 [9].
When IL-6 binds to membrane-bound IL-6R (mIL-6R), the
homodimerization of gp130 is induced, and a high-aﬃnity
functional receptor complex of IL-6, IL-6R, and gp130 is
formed. On the other hand, the soluble IL-6R (sIL-6R),
lacking the intracytoplasmic portion of mIL-6R, is produced
either by the enzymatic cleavage of mIL-6R or by alternative
splicing. sIL-6R can bind with IL-6 and then the complex of
IL-6andsIL-6Rcanformthecomplexwithgp130(Figure 1).
This unique receptor signal is termed IL-6 transsignaling
[10]. Tocilizumab is able to bind to both sIL-6R and mIL-
6R and to inhibit IL-6 binding to its receptors, leading to the
blockade of the IL-6 signaling through both receptors [11].
Membrane bound gp130 (mgp130) is expressed ubiqui-
touslyinthebody.Therefore,theIL-6/sIL-6Rcomplexcould,
theoretically, stimulate most cells of the body. However, this
transsignaling is thought to be highly regulated by soluble
gp130 (sgp130), which is found at higher concentrations in
blood. sgp130 binds IL-6/sIL-6R complex and then inhibits
the binding of IL-6/sIL-6R complex to mgp130 [12, 13].
Namely, sgp130 is a natural inhibitor of IL-6 signaling.
As mentioned above, many components participate in
IL-6 signaling system. It enlarges the spectrum of IL-6 target
cells because cells which do not express a mIL-6R can be
stimulated by IL-6 and sIL-6R. Moreover, since hepatocytes
express far more gp130 than mIL-6R, it has been shown
that IL-6/sIL-6R has more eﬀective on hepatocytes than IL-6
alone [14, 15].
3. IL-6and Soluble IL-6Receptor in RA Patients
Overproduction of IL-6 has been found in the synovial ﬂuid
and blood of RA patients, and IL-6 levels correlate with
disease activity [16, 17]. On the other hand, sIL-6R is present
in the blood of both healthy subjects and RA patients, and
the concentration is comparable between healthy subjects
and RA patients. In contrast, a higher concentration of
sIL-6R is detectable in the synovial ﬂuid of RA patients
than is found in the synovial ﬂuid of osteoarthritis patients
[18].Inﬂammatorycellssuchasmonocytesandlymphocytes
inﬁltrating into the synovium are considered to be a source
of sIL-6R.
4.Roles ofIL-6 inSynovitis
Changes in the synovium are marked by neovascularization,
inﬁltration of inﬂammatory cells, and synoviocyte hyper-
plasia that act together to produce a pannus (inﬂammatory
vascular tissue). Newly formed blood vessels are thought to
beinvolvedinthedevelopmentandmaintenanceofsynovitis
because they support the inﬁltration of inﬂammatory cells
and the growth and survival of synovial cells.
Although a number of growth factors and cytokines
have angiogenic activity, vascular endothelial growth factor
(VEGF) is thought to be the most important angiogenic
factor in the pathogenesis of RA [19]. Signiﬁcant increases
in VEGF levels in RA patients correlate with disease activity,
suggesting that VEGF is implicated in RA pathogenesis, par-
ticularly in pannus formation. In RA patients, VEGF levels
in blood are elevated and treatment with TCZ signiﬁcantly
lowers VEGF levels [20]. IL-6 induced tubule formation in
a coculture system of human umbilical venous endothelial
cells (HUVECs) and ﬁbroblast-like synoviocytes from RA
patients (RA-FLS) and that this angiogenesis was completely
inhibitedbyanti-VEGFantibody,indicatingthatVEGFplays
a crucial role in IL-6-induced angiogenesis [21].
TCZ treatment signiﬁcantly reduced joint swelling and
the inﬁltration of inﬂammatory cells into inﬂamed joints
in monkey collagen-induced arthritis (CIA), when TCZ was
injected after the onset of arthritis [22]. IL-6 augmented
production of chemokines such as monocyte chemotactic
protein-1(MCP-1)andIL-8fromendothelialcells,mononu-
clearcells,andRA-FLS,andalsoinducedadhesionmolecules
such as ICAM-1 in endothelial cells and increased adhesion
of monocytes to endothelial cells [23, 24]. These lines of
evidence strongly support the idea that IL-6 aggravates the
local inﬂammatory reaction by amplifying inﬂammatory cell
inﬁltration. Suppression of angiogenesis may also reduce cell
migration, because newly formed blood vessels are conduits
for the inﬁltration of inﬂammatory cells.
Synovial ﬁbroblastic cells produced large amounts of
IL-6 when stimulated by inﬂammatory cytokines such as
IL-1, TNFα, and IL-17, and that IL-6 augmented the
proliferation of synovial ﬁbroblastic cells in the presence
of sIL-6R [25, 26] .T C Zm a ye x e r ti t sa n t i s y n o v i t i se ﬀect
via the inhibition of these biological activities of IL-6. In
fact, semiquantitative ultrasonographic assessment clearly
indicatesthatTCZtreatmentsigniﬁcantlyimprovessynovitis
in RA patients [27].
5. Roles of IL-6 inJoint Damage
Irreversible joint destruction is a characteristic feature of RA.
TCZ monotherapy for 52 weeks showed signiﬁcantly less
radiographic change in total Sharp score (bone erosion and
joint space narrowing) than DMARD treatment [28].Arthritis 3
As a pathogenic mechanism of bone destruction, osteo-
clasts activated by inﬂammatory cytokines are thought to be
responsible for focal bone erosion. Indeed, osteoclasts are
often seen in the synovium at sites of cartilage destruction
in RA patients [29, 30]. The receptor activator of NF-
κB (RANK) and its ligand (RANKL) are essential factors
for osteoclastogenesis [31–33]. IL-6 and sIL-6R, but not
IL-6 alone, induced RANKL expression in RA-FLS. On
the other hand, TNFα and IL-17 did not induce RANKL
expression, although both stimulate cell growth and IL-6
production. Interestingly, in the presence of sIL-6R, TNFα or
IL-17 induced RANKL expression (Figure 2). In a coculture
of RA-FLS and osteoclast precursor cells, IL-6 and sIL-
6R induced NFATc1 and TRAP5b mRNA expression in
the osteoclast precursor cells. IL-6/sIL-6R directly induced
osteoclastogenesis by inducing RANKL expression in RA-
FLS [26]. Moreover, in mouse calvarial bone cultures, IL-
6, in the presence of sIL-6R, induced bone resorption,
which was decreased by osteoclast inhibitors, suggesting
that IL-6 signaling inﬂuences osteoclastogenesis induced by
osteoblast and osteoclast interaction [34]. From these facts,
IL-6 induces osteoclast formation by inducing RANKL in
RA-FLS as well as osteoblast.
Cartilage degeneration is also observed in RA joints.
RANKL inhibition clearly halted the progression of bone
erosion, but did not improve joint space narrowing in RA
patients, strongly suggesting that RANKL/RANK signaling
does not participate in cartilage degeneration in RA patients
[35]. Matrix metalloproteinases (MMPs) and a disintegrin
and metalloproteinase with thrombospondin-like repeat
(ADAMTSs) are thought to play crucial roles in cartilage
matrix degeneration. IL-6 induced MMP-1, MMP-3, and
MMP-13 production from chondrocytes and synovial
cells [36, 37]. On the other hand, it is reported that tissue
inhibitors of MMPs (TIMPs) are endogenous inhibitors
of MMPs. IL-6, in the presence of sIL-6R, induced the
production of TIMP in cultured human chondrocytes and
synovial ﬁbroblasts, suggesting that IL-6 plays a role in
extracellular matrix turnover [38].
These data suggest that the preventive eﬀect of TCZ
on joint destruction is mediated by the inhibition of IL-6-
induced RANKL induction followed by osteoclastogenesis
and suppression of the IL-6-induced production of MMPs.
In the SAMURAI and OPTION studies, improvement in a
bone resorption marker (C-terminal cross-linking telopep-
tide of type I collagen) and in cartilage turnover markers
(N-terminal propeptide of type IIA collagen and type II
collagenhelicalpeptide)wereseenintheTCZgroup[28,39].
Moreover, tocilizumab decreased serum MMP-3 levels in
several clinical trials [40–42].
6. Roles in Autoimmunity
There is no doubt that T cells play important roles in the
onset of RA. CD4+T helper cells have been classiﬁed as
Th1a n dT h2 cells on the basis of their cytokine production
proﬁles, and, recently, Th1 7c e l l sw h i c hp r o d u c eI L - 1 7
in autoimmune pathology have become recognized as a
separate subset, which is interesting in the context of events
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Figure 2: Mechanism of RANKL induction by cytokines.
that were previously thought to be Th1-mediated. In vitro
studiesinmicehaveshownthatthecostimulationofIL-6and
TGF-β is essential for the diﬀerentiation of Th17 cells from
na¨ ıve CD4+ T cells [43]. Furthermore, studies suggesting an
involvement of IL-6 in the induction of Th17 cells in arthritis
models have been reported: anti-IL-6R antibody suppressed
the onset of arthritis in G6PI-induced and collagen-induced
arthritis models and concomitantly inhibited the appearance
of Th17 cells [44, 45]. The involvement of Th17 cells in RA
is, therefore, still controversial. However, the involvement
of CD4+CD161+ T cells in autoimmune diseases has been
attracting attention recently [46]. These T cells produce large
amounts of IL-17 and are increased in psoriasis and Crohn’s
disease.Itisalsoreportedthatperipheralbloodmononuclear
cells (PBMC) from RA patients produced higher levels of IL-
17 than PBMC from healthy subjects when stimulated with
anti-CD3 and anti-CD28 antibodies [47] .T h er o l eo fI L - 1 7
producing T cells in RA will be clariﬁed in the near future.
Moreover, RA is characterized by an increase in IgM
and IgG rheumatoid factors and antibodies to citrullinated
peptides in both serum and joints. B-cell depletion is of
therapeutic beneﬁt in RA and demonstrates the impact of
B-cell activity on synovial inﬂammation and joint damage
in this disease. IL-6 was originally identiﬁed as a B-cell
diﬀerentiation factor; it plays an important role in the
development of antibody-producing plasma B cells [48]. IL-
6 induces B-cell diﬀerentiation through its action on plas-
mablasts [49] and more recently has been shown to induce
B-cell antibody production indirectly by promoting the B-
cell helper properties of CD4+ T cells via the production of
IL-21 [50]. Indeed, TCZ treatment decreased frequency of
circulating plasma cells in SLE patients [51].
7 .R o l e so fIL - 6inA n e m iao fR A
Anemia is the most common extra-articular manifestation
of RA and is estimated to occur in 30% to 60% of patients
[52, 53]. There are two primary types of anemia in RA: ane-
mia of chronic disease (ACD) and iron-deﬁciency anemia.
ACD is characterized by hypoferremia in the presence of
adequate iron stores. ACD is an inﬂammatory anemia, and4 Arthritis
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Figure 3: Hepcidin mRNA induction by arthritic serum in Hep3B
cells [7]. Hep3B cells were incubated with serum from healthy,
arthritic, or tocilizumab-treated monkeys for 24h. Tocilizumab was
added simultaneously with serum. After incubation, total mRNA
was extracted, and hepcidin mRNA was measured by real-time
PCR. The hepcidin expression induced by medium alone (without
serum) was deﬁned as 1. Each point represents the mean and
SD of 3 monkeys. Statistical signiﬁcances between healthy animals
and arthritic animals and between control and the addition of
tocilizumab were analyzed by unpaired t-test. ∗P<. 05 (healthy
animals’ serum, control versus arthritic animals’ serum, control),
†P<. 05 (arthritic animals’ serum, control versus arthritic animals’
serum, tocilizumab).
inﬂammatory cytokines are thought to play important roles
in anemia in RA [54, 55]. In fact, TCZ therapy in RA patients
rapidly improves anemia [40].
Anemia was also induced in monkey CIA after col-
lagen immunization. Anemia in monkeys with CIA is
characterized by decreased serum iron and transferrin (Tf)-
saturation, and by elevated serum ferritin, and its severity
is correlated with serum IL-6 levels; therefore, anemia in
monkeys with CIA is very similar to human anemia in
inﬂammatory diseases, at least with respect to the changes in
serum parameters [7]. Hepcidin is a master regulator of iron
homeostasis in humans and other mammals [56]. It inhibits
the absorption of iron in the small intestine and the release
of recycled iron from macrophages, eﬀectively decreasing the
deliveryofirontomaturingerythrocytesinthebonemarrow
[8]. In fact, mice genetically engineered to overproduce
hepcidin die of severe iron deﬁciency shortly after birth [57].
Interestingly, IL-6 induces hepcidin production in liver cells
[58].
Administration of TCZ to monkeys with CIA rapidly
improved anemia and induced a rapid but transient reduc-
tion in serum hepcidin. Hepcidin mRNA expression was
more potently induced by serum from arthritic monkeys,
and this was inhibited by the addition of TCZ (Figure 3)
[59]. From these lines of evidence, we propose that TCZ
improves anemia in monkey arthritis via the inhibition of
IL-6-induced hepcidin production.
8. Roles of IL-6 in Hypolipidemia
Cholesterolandtriglyceridelevelsappearnormalorevenlow
inpatientswithearlyactiveRAandhigh-gradeinﬂammation
[60]. We previously reported that IL-6-treated mice had low
total cholesterol (TC) and triglyceride (TG) levels compared
with PBS-treated mice (Figure 4)[ 61]. In this model, we
conﬁrmed that expression of the VLDL receptor, which
plays a role in the delivery of fatty acids derived from
VLDL-triglycerides from the blood to peripheral tissues,
was upregulated in IL-6-treated mice. From these results, it
is suggested that the induction of VLDL receptor by IL-6
may be related to the hypolipidemia. Several reports have
described the function of IL-6 in lipid metabolism in adipose
tissue. Interstitial IL-6 concentrations in adipose tissue are
∼100-fold higher than in plasma, implying an important
auto- and paracrine regulatory function in this tissue [62].
IL-6 has lipolytic properties and increases lypolysis of
adipose tissue and adipocytes in vitro [63, 64]. Consistent
withtheseinvitrostudies,IL-6infusioninhumansincreased
free fatty acid and whole body fat oxidation [65].
It is reported that treatment of RA patients with TCZ
increased blood levels of TC, TG, and HDL-cholesterol in a
manner inversely related to the disease activity of RA [66]. It
is also reported that blockade of TNFα increased blood levels
of TC, TG, and HDL-cholesterol, and that the persistent
inﬂammatory condition reﬂected by elevated serum TNFα
levels results in low levels of TC and TG in RA [67–69]. This
fact strongly suggests that the inhibition of IL-6 production
induced by TNFα blockade results in an increase of lipids.
Anyway, both TNFα blockade and TCZ did not change the
atherogenic index (TC/HDL) although these drugs increased
TC and TG [70, 71].
9. Conclusion
IL-6 is considered to play a central role in chronic inﬂamma-
tion and is expressed in excess at sites of inﬂammation. IL-6
levels are considerably elevated in the serum of RA patients,
and this elevation has been directly correlated with clinical
indices of disease activity. In addition, high levels of sIL-
6R have been shown to correlate with the degree of joint
destruction, in particular, in advanced stages of RA. IL-6 is
a multitarget cytokine with activity relevant to RA. At the
aﬀected joints, IL-6 has a pivotal role in the inﬂammatory
process, in osteoclast-mediated bone resorption, and in
synovitis (Figure 5). IL-6 induces acute-phase proteins and
contributes to the systemic manifestations of RA though
hepcidin production (anemia) and acts potently in chang-
ing lipid concentrations (hypolipidemia). In addition, IL-
6 may contribute to the induction and maintenance of
the autoimmunity through B-cell activation and Th17 cell
diﬀerentiation.
TCZ has been recently approved for the treatment
of adult patients with moderately to severely active RA
with inadequate response to one or more DMARDs or
TNF antagonists. TCZ not only improves local signs and
symptoms, but also systemic ones, such as anemia, anorexia,
fever, and fatigue, thereby potentially improving patientArthritis 5
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Figure 5: Mode of action of tocilizumab.
QOL. Infection is among the most common adverse eﬀect
of cytokine inhibitors. Although the incidence of infections
is similar to that with other biologics and most episodes
are not serious and can be straightforwardly managed,
TCZ signiﬁcantly reduces inﬂammatory markers such as
CRP. When administering TCZ, it is important to pay
attention not only to abnormal test values associated with
infection but also to the emergence of symptoms of infection
in the patients. It is also important to educate patients
who are going to be treated with TCZ that they should
come in promptly for treatment if they notice any physical
abnormalities, such as cough or sputum.
Inconclusion,IL-6participatesinboththeinﬂammation
andautoimmunityofRApatients.Therefore,theblockadeof
IL-6 is a beneﬁcial therapy for RA patients.
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